Note: Descriptions are shown in the official language in which they were submitted.
CA 02720132 2010-09-23
WO 2009/137560 PCT/US2009/042958
METHOD OF MEASURING EFFECTS OF COMPONENTS ON
CELL REACTIVE OXYGEN SPECIES PRODUCTION
BACKGROUND OF THE INVENTION
100011 Reactive oxygen species (ROS) are cellular byproducts formed by the
metabolism of
oxygen, are responsible for cell oxidative damages, and can be the cause of
cellular injury, cellular
dysfunction, and cell death (apoptosis). The effects of ROS on cell metabolism
have been well
documented. Accumulation of ROS in tissue may cause oxidative injury, and thus
it may be
desirable to reduce the amounts of ROS in tissues. It is desirable to monitor
ROS generation in
cells to determine whether ROS are involved in diseases including
cardiovascular, inflammatory,
and infectious diseases. Cells normally are capable of preventing oxidative
damage from ROS
with enzymes, such as superoxide dismutase or catalase. Other compounds also
are useful in
preventing such damage, including antioxidants such as vitamins, uric acid,
and glutathione. Such
compounds, (e.g., antioxidants), may play an important role in scavenging free
radicals and
protecting the host organism from pathogens.
[0002] Although many methods have been developed to measure ROS quantities in
tissue, there
are few methods that measure intracellular ROS concentrations in real time.
The ability to
measure ROS quantities is important, in that ROS concentrations may change,
e.g., increase or
decrease, over time.
[0003] Accordingly, there is a continuing interest in developing and
administering effective
antioxidant compositions to prevent ROS damage. There are few methods,
however, that are
capable of measuring the effects of compositions on ROS production in real
time. It therefore
would be desirable to develop methods that can measure the effects of
components on intracellular
ROS production.
BRIEF SUMMARY OF THE INVENTION
[0004] In accordance with certain embodiments, a method is provided that can
be utilized to
measure intracellular ROS concentrations in real time. The method of the
embodiments may be
useful in determining the effects of test components on intracellular ROS
production and oxidative
stress on a cell. The methods also may be useful to determine the ability of
test components to
reduce ROS components in a cell, in which the ROS which may be endogenous or
exogenous to
the cell.
1
CA 02720132 2013-06-11
62301-2967
[0005] Thus, certain embodiments described herein include a method of
measuring the
effect a test component has on the production of ROS in a cell. The method
includes
contacting a cell with a material capable of fluorescence, contacting the cell
with a test
component, contacting the cell with an ROS or an ROS stimulant, and measuring
cell
fluorescence. The embodiments further include measuring cell fluorescence
after contacting
the cell with the material capable of fluorescence and either an ROS or an ROS
stimulant,
measuring cell fluorescence after contacting the cell with a test component,
comparing the
two fluorescence values and determining whether the test component reduced
ROS.
[0005a] An aspect of the invention relates to a method of measuring
the efficacy of a
test component in reducing reactive oxygen species (ROS) components in oral
bacteria,
comprising: (a) contacting the cell with a material capable of fluorescence;
(b) contacting the
cell with the test component; (c) contacting the cell with an ROS and an ROS
stimulant,
wherein the ROS is selected from the group consisting of an oxygen ion
generating
compound, a free radical generating compound, a peroxide, and mixtures
thereof, and wherein
the ROS stimulant is selected from the group consisting of bacterial
endotoxin, exotoxin, and
mixtures thereof, or comprises a lipopolysaccharide.
[0005b] An aspect of the invention relates to a method of measuring
the efficacy of a
test component in reducing reactive oxygen species (ROS) components in oral
bacteria
comprising: (a) contacting the cell with a material capable of fluorescence;
(b) contacting the
cell with the test component; (c) measuring cell fluorescence; (d) contacting
the cell with an
ROS and an ROS stimulant wherein the ROS is selected from the group consisting
of an
oxygen ion generating compound, a free radical generating compound, a
peroxide, and
mixtures thereof, and wherein the ROS stimulant is selected from the group
consisting of
bacterial endotoxin, exotoxin, and mixtures thereof, or comprises a
lipopolysaccharide;
(e) measuring cell fluorescence; and (0 comparing the cell fluorescence from
(c) with the
fluorescence from (e) and determining the efficacy of the test component in
reducing ROS.
2
CA 02720132 2013-06-11
62301-2967
BRIEF DESCRIPTION OF THE DRAWINGS
[0006] FIG. 1 shows the fluorescence values obtained in Example 1;
and
[0007] FIG. 2 shows the fluorescence values for various test
components, as described
in Example 1.
DETAILED DESCRIPTION OF THE INVENTION
[0008] As used throughout this description, ranges are used as a
shorthand for
describing each and every value that is within the range. Any value within the
range can be
selected as the terminus of the range. In the event of a conflict in a
definition in the present
disclosure and that of a cited reference, the present disclosure controls.
[0009] Unless otherwise specified, all percentages and amounts expressed
herein and
elsewhere in the specification should be understood to refer to percentages by
weight. The
amounts given are based on the active weight of the material.
[0010] Throughout this description, use of articles "the", "a", "an",
or the like is not
intended to limit the embodiments to a singular form of the item. For example,
the expression
"a component" can denote a single component or multiple components. Component
in the
embodiments includes chemical compounds, small and large peptides and
proteins, DNA that
express small and large peptides and proteins, and the like.
[0011] The method includes contacting a cell with a material capable
of fluorescence
when oxidized or reduced, contacting the cell with a test component,
contacting the cell with
an ROS or an ROS stimulant, and measuring cell fluorescence. Preferably, the
material
capable of fluorescence is a dye that fluoresces when oxidized, more
preferably a dye selected
from 2,7-
2a
CA 02720132 2010-09-23
WO 2009/137560 PCT/US2009/042958
dichlorofluorescein diacetate (DCF-DA), dihydrorhodamine (DHR 123), and
mixtures thereof
The method also includes use of a material that is capable of fluorescence
when reduced.
[0012] A preferred method includes the use of an antioxidant as the test
compound. Another
preferred method includes as the ROS an oxygen ion generating compound, free
radical
generating compound, a peroxide, or combinations thereof Preferably the ROS is
a peroxide, and
more preferably hydrogen peroxide. Other preferred methods include the use of
an ROS
stimulant, such as an inflammatory mediator.
100131 The method of the preferred embodiments also includes as the ROS
stimulant: (i) a
bacterial endotoxin, exotoxin, or combinations thereof; or (ii) a
lipopolysaccharide,
lipooligosaccharide, or combinations thereof Preferably, the ROS is a
lipopolysaccharide.
[0014] A cell useful with various methods of preferred embodiments include an
immune cell, a
lymphocyte, lymphoblast, macrophage, a nucleated cell such as mitochondria, or
mixtures thereof.
The cell may be immortalized, or present in a tissue culture. Preferably, the
cell has a cell wall
that is permeable by a dye. In addition, the dye may accumulate in the cell
mitochondria. It is
preferred that any excess dye is washed from the cell.
[0015] In the method of the preferred embodiments, the test compound is
transported into the cell,
either actively or passively. Preferably, any excess test compound is washed
from the cell. In a
similar vein, the ROS or ROS stimulant (e.g., inflammatory mediator)
preferably is transported
into the cell, either actively or passively, and it is preferred to wash any
excess ROS or ROS
stimulant from the cell.
[0016] In accordance with various aspects of preferred embodiments, a cell
initially is contacted
with a material capable of fluorescence when oxidized or reduced, preferably a
dye. Dyes useful
in the present embodiments include dyes That fluoresce when oxidized or
reduced. Preferably,
such dyes fluoresce when oxidized or reduced, e.g., by a ROS. It is preferred
to use dyes that are
contacted with cells in a non-fluorescent form, and then fluoresce when
reacted with a ROS, e.g.,
ROS either produced intracellularly or introduced from external sources. Some
useful dyes that
possess these attributes are known to those having ordinary skill in the art,
and may include
fluorescein type dyes, such as 2,7-dichlorofluorescein diacetate (DCF-DA). DCF-
DA is a
membrane-permeable dye that may diffuse across the cell lipid membrane. It is
non-fluorescent
when inactive, and forms a highly fluorescent dicholofluorescein (DCF) when it
is oxidized by
ROS. Other dyes useful in the present invention may include fluorescein
derivatives and analogs,
such as dihydrorhodamine (DHR 123), which is an analog of DCF-DA. DHR123
accumulates in
3
CA 02720132 2010-09-23
WO 2009/137560 PCT/US2009/042958
mitochondria, and therefore may be particularly useful in determining ROS
levels in the same.
Other useful dyes may include derivatives of fluorescein, such as Oregon
Green, Tokyo Green,
carboxyseminaphthofluorescein (SNAFL ¨ available from Molecular Probes,
(Invitrogen Corp.),
Carlsbad, CA), carboxynaphthofluorescein, Alexa Fluor dyes (e.g., Alexa 488 ¨
also available
from Molecular Probes, (Invitrogen Corp.), Carlsbad, CA), DyLight Fluor dyes
(e.g., DyLight
488, commercially available from Thermo Fisher Scientific, Waltham, MA), and
HiLyte Fluor
dyes (commercially available from AnaSpec, San Jose, CA). The cells may be
incubated with the
dye to allow for incorporation of the dye into the cell. Afterwards, the cells
may be washed to
remove residual dye.
[0017] Following labeling with a dye, the cell may be exposed to one or more
test compounds.
Such test compounds preferably are introduced into the cell by active or
passive transport, e.g.,
diffusion, and are preferably retained within the cell. The cells may be
incubated in the presence
of such test compounds, and then washed to remove residual test compounds.
[0018] Following treatment with the test compound, the cell then preferably is
exposed to
ROS. ROS typically include oxygen ions, free radicals, and peroxides, both
inorganic and
organic, and compounds that generate such oxygen ions and free radicals
intracellularly. ROS (or
ROS agents) are known to those having ordinary skill in the art, and generally
are small molecules
that are highly reactive due to the presence of unpaired valence shell
electrons. Examples of
peroxides include hydroperoxides, hydrogen peroxide, peroxides of alkali and
alkaline earth
metals, organic peroxy compounds, peroxy acids, and mixtures thereof. The cell
may be exposed
to the ROS agents from an external source, in which the cell may be incubated
in media
containing the ROS agent to allow for the cell to incorporate the ROS agent
intracellularly, e.g.,
either by active or passive transport. The cells then may be washed to removed
residual ROS that
has not been incorporated into the cell.
[0019] In one embodiment of the present invention, ROS may be contacted with a
cell in
conjunction with a compound that induces ROS production, e.g., a ROS
stimulant, such as an
inflammatory mediator in which the mediator causes or is known to cause ROS
production in a
cell. In yet another embodiment the cell is contacted with the ROS stimulant
in the absence of the
additional ROS agent. As is known in the art, the inflammatory mediator may
include a bacterial
toxin, e.g., an endotoxin or exotoxin, such as a lipopolysaccharide or
lipooligosaccharide. The
cell may be incubated with the ROS and inflammatory mediator so as to allow
the ROS and
inflammatory mediator to be incorporated into the cell. The cell may then be
washed to remove
4
CA 02720132 2010-09-23
WO 2009/137560 PCT/US2009/042958
residual ROS and inflammatory mediator. Alternatively, the cell may be
incubated with the
inflammatory mediator so as to allow the inflammatory mediator to be
incorporated into the cell.
The cell then may be washed to remove residual inflammatory mediator.
[0020] The methods of the embodiments described herein contemplate measuring
fluorescence of
the cells that have been contacted with the various components. The methods
include measuring
fluorescence after contacting the cells with the material capable of
fluorescence and the ROS or
ROS stimulant, and then measuring fluorescences after contacting the cells
with these components
and the test compound. Fluorescence may be determined by any method known by
those having
ordinary skill in the art and readily available. Such known and commercially
available methods
include optical live cell array technology or microscope imaging systems. As
is well known,
fluorescence typically is measured at excitation and at emission. Persons
having ordinary skill in
the art are capable of measuring and determining fluorescence, using the
guidelines provided
herein.
[0021] Without intending to be bound by any theory, it is believed that the
methods of the present
invention allows for real-time analysis of the effects of test compounds on
intracellular ROS
levels. By incorporating a component capable of fluorescence, a test compound,
and then a
ROS/inflammatory mediator into the cells, one is able to measure the
antioxidant activity of the
test compound by measuring cell fluorescence. The component capable of
fluorescence upon
oxidation or reduction, preferably a dye, typically has some background
fluorescence, but upon
binding to free radicals, the fluorescence intensity increases. That increase
in fluorescence
intensity can readily be measured. Test compounds can be added to the cells to
assess their ability
to reduce the formation of ROS free radicals (or consume them by reaction),
and if capable of
reducing free radical formation, the fluorescence intensity should decrease.
[0022] Accordingly, a test compound that has a greater ability to inhibit ROS
results in a reaction
in which less ROS is able to react with the dye, and thus there is reduced
fluorescence. On the
other hand, a test compound that does not inhibit ROS results in a reaction in
which a greater
amount of ROS is able to react with the dye, and thus there is increased
fluorescence. Cellular
fluorescence may be monitored over a period of minutes, hours, or days to
determine the effect of
the test compound on the ROS/inflammatory mediator.
[0023] In one embodiment, the cell is contacted with a dye before being
contacted with a test
compound. Optionally, the cell is contacted with a test compound before being
contacted with a
CA 02720132 2010-09-23
WO 2009/137560 PCT/US2009/042958
ROS and/or ROS stimulant. In another embodiment, the ROS is introduced into
the cell, e.g., the
ROS is exogenous to the cell.
[0024] Cells useful in the preferred methods include nucleated cells having
mitochondria. The
cells may be immortalized, e.g., cancer cells, and may be immune cells, such
as a lymphocyte, or
lymphoblast cells. Such cells may be cultured in any number of methods known
by those of skill
in the art. The cells also may be cultured on-site during an operative or
examination procedure,
and then tested in real time to assess the effects of certain test compounds
on inhibiting cellular
production of ROS.
[0025] The methods of the embodiments are useful in determining the effects
compounds have on
the production of ROS in cells. As stated above, it is known that the
generation of free radicals in
a cell is undesirable, often resulting in cell death. For example, certain
bacteria have the effect of
inducing free radical formation in human cells and consequently, damage the
cells. The methods
described herein are capable of determining test compounds that can reduce
free radical formation
(resulting in lower fluorescent intensity), and thus may be useful in counter-
acting the deleterious
effects of the bacteria.
[0026] Many such bacteria exist in the oral cavity and oral mucosa. The
bacteria may cause any
number of deleterious effects. For example, bacterial cells may be used as the
cells of the
preferred embodiments, preferably, facultative anaerobe cells. The method then
can measure the
ability of certain test compounds to reduce the free radical generation of
such cells.
[0027] The methods of the embodiments therefore can be used on-site to
determine an effective
therapy (administration of an efficacious test compound that adequately
reduced fluorescence) for
treating certain cells susceptible to free radical generation. The methods of
the embodiments also
are useful in demonstrating the efficacy of certain compounds (or compositions
containing these
compounds) on known cells, e.g., bacterial cells. For example, the method can
be used to show a
dental professional how effective a certain dentifrice is in reducing free
radical generation in
bacteria cells commonly found in the human mouth. The method also can be used
as a
comparative tool in marketing a product by showing comparisons between
products (e.g.,
dentifrices of various competitors).
[0028] The preferred embodiments of invention now will be described with
respect to the
following non-limiting example. The example is merely illustrative and does
not in any way limit
the scope of the invention as described and claimed.
6
CA 02720132 2010-09-23
WO 2009/137560 PCT/US2009/042958
EXAMPLE 1
[0029] Human histocytic lymphoma U937 cells (ATCC, Manassas, VA) were
initially cultured in
RPMI-1640 media (ATCC, Manassas, VA) containing 10% serum and 1% penicillin,
and then
transferred at a concentration of 2 X 105 cells/m1 into media containing
lng/ml PMA for 48 hours
at 37 C. The cells were starved overnight in serum-free culture media before
exposure to dye.
[0030] Cells were washed with PBS buffer twice, and divided into two sets to
be incubated with
DCF-DA or DHR123 (Calibochem, La Jolla, CA) for 30 minutes at 30 C. Cells are
washed with
PBS twice to remove residual dye. Appropriate experimental controls are also
maintained.
[0031] Cells are then divided into several groups, and various amounts of a 1%
solution of a-
tocopherol (Vitamin E), substance 1, or substance 2 is added to each of the
groups, and incubated
at 37 C for 15 minutes. Cells then were washed twice with PBS to remove
residual amounts of
test compounds. ROS agents H202 and LPS then were added and incubated for
different periods
of time. Fluorescence of the cells then were read at excitation 485 nm and
emission 530 nm for
up to 5 hours.
[0032] As shown in Figures 1 and 2, cells stained only with dye, e.g., DCF-DA
and DHR123
exhibit background fluorescence. Referring to Figure 1, following two hours of
incubation, cells
incubated in the absence of a test compound but in the presence of the ROS at
2.5 mM and ROS
stimulant fluoresce greater than cells incubated in the presence of a test
compound (a-tocopherol)
and ROS at 2.5 mM and ROS stimulant.
[0033] Analysis of cell fluorescence therefore allows real-time monitoring of
intracellular
oxidative stress that can be used to screen test compounds. Measurement of
cell fluorescence may
be accomplished with optical live cell array technology, and/or microscope
imaging systems in
individual cells.
[0034] Referring to Figure 2, 2ppm, 10 ppm, or 100 ppm of a-tocopherol,
substance 1, and
substance 2 were incubated with the cells. Figure 2 reveals that in the
presence of 2.5mM of
hydrogen peroxide, 2ppm of a-tocopherol and substance 1 reacted with ROS and
reduced the
oxidative level by approximately 30%. At lOppm and 100ppm, a-tocopherol did
not show
enhanced capability in scavenging ROS or free radicals; however, 100ppm of
substance 1 reduced
the oxidative level by 50%. Figure 2 also reveals that substance 2 enhanced
the oxidative level,
and that substance 2 increased to nearly 3 times the free radical level at
100ppm, when compared
to 2 ppm.
7
CA 02720132 2012-10-16
62301-2967
[0035] It will be appreciated by those having ordinary skill in the
art that
changes and alterations may be made to the embodiments described above without
departing from the broad inventive concept thereof. It is understood,
therefore, that
this invention is not limited to the particular embodiments disclosed, but it
is intended
to cover modifications within the scope of the present invention.
8
